|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Revenue: | ||
| License and collaboration revenue | ||
| Total revenue | ||
| Operating expenses: | ||
| Research and development | ||
| General and administrative | ||
| Acquired in-process research and development | ||
| Total operating expenses | ||
| Loss from operations | ||
| Other income (expense), net: | ||
| Fair value adjustments to convertible notes | ||
| Interest expense on royalty obligation | ||
| Interest income | ||
| Other income, net | ||
| Total other income (expense), net | ||
| Loss before income taxes | ||
| Income tax (benefit) provision | ||
| Net loss | ||
| Other comprehensive income (loss): | ||
| Unrealized gain on investments | ||
| Foreign currency translation adjustment | ||
| Comprehensive loss | ||
| Net loss per share - basic (in dollars per share) | ||
| Net loss per share - diluted (in dollars per share) | ||
| Weighted-average common stock outstanding - basic (in shares) | ||
| Weighted-average common stock outstanding - diluted (in shares) |
Loading...
